Melatonin administration increased plasminogen activator activity in ram spermatozoa.
The aim of the present study was to investigate the effect of melatonin on plasminogen activator activity (PAA), plasminogen activator inhibition (PAI) and plasmin inhibition (PI) in ram spermatozoa and seminal plasma, in correlation with changes in blood testosterone. Melatonin implants (18 mg) were placed subcutaneously in sixteen Chios rams in autumn and spring. Semen samples for spectrophotometrical assays were collected 36 h before the implantation of melatonin and thereafter once a week, for 17 weeks. Blood samples for testosterone assay (RIA) were collected 8h before implantation (one sample/30 min x 7.5 h) and thereafter every 15 days for 105 days after implantation. For each ram, six parameters of testosterone were estimated: mean value, basal level, number of peaks, peak amplitude, peak duration and mean testosterone concentration during peaks. Melatonin implantation during autumn induced an increase in PAA and t-PAI in spermatozoa; melatonin implantation in spring induced an additional increase in u-PAI and PI; no change in PAA, PAI or PI was found in seminal plasma, during autumn or spring. The melatonin-induced increase of PAA, PAI and PI in spermatozoa was in positive correlation with the increase of testosterone mean value, basal level and number of peaks; the increase of testosterone parameters was greater in autumn compared to spring. Changes of PAA, PAI and PI of spermatozoa, under the influence of melatonin, might indicate changes in the fertilizing ability of spermatozoa, since plasminogen activators and their inhibitors are present on the plasma and the outer acrosomal membrane of spermatozoa and are released during the acrosome reaction.
Tsantarliotou
M P
MP
Department of Physiology, School of Veterinary Medicine, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece. mtsant@vet.auth.gr
Kokolis
N A
NA
Smokovitis
A
A
D000818:Animals; D000933:Antifibrinolytic Agents / Q000032:analysis; D004343:Drug Implants; D006115:Greece; D008297:Male; D008550:Melatonin / Q000008:administration & dosage*; D010960:Plasminogen Activators / Q000032:analysis / Q000378:metabolism*; D015849:Plasminogen Inactivators / Q000032:analysis; D012621:Seasons; D012661:Semen / Q000737:chemistry / Q000201:enzymology; D012756:Sheep / Q000378:metabolism*; D013094:Spermatozoa / Q000737:chemistry / Q000201:enzymology / Q000378:metabolism*; D013739:Testosterone / Q000097:blood; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors
D000933:Antifibrinolytic Agents; D004343:Drug Implants; D015849:Plasminogen Inactivators; D013739:Testosterone; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator; D008550:Melatonin